3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Rhabdoid Tumor
1
Respiratory Tract Diseases
1
Papillary renal cell carcinoma, sporadic
1
Pancreatic Intraductal Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hereditary leiomyomatosis and renal cell cancer
1
Interventions
Carboplatin
46
Etoposide
45
durvalumab
28
atezolizumab
26
Cisplatin
21
Topotecan
19
pembrolizumab
15
PM 01183
14
Nivolumab
12
Specimen Handling
11
Drug Therapy
10
anlotinib
9
Radiotherapy
9
Paclitaxel
9
Temozolomide
8
Magnetic Resonance Spectroscopy
8
AMG 757
8
Radiosurgery
7
Platinum
7
Irinotecan
7
toripalimab
6
olaparib
6
Biopsy
6
Ipilimumab
5
Injections
5
Docetaxel
5
Bevacizumab
5
trilaciclib
4
tremelimumab
4
tislelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
Erlotinib Hydrochloride
×
1 year
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled